TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29771807

Group type: EXPERIMENTAL
Intervention: Oral isotonic glucose-sodium hydration solution for 40 days postdischarge
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nonileostomy group (n = 37)
Number of subjects: 80
Study: 27048897

Group type: EXPERIMENTAL
Intervention: Probiotics (VSL#3 or E. Coli Nissle 1917)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 26703919

Group type: EXPERIMENTAL
Intervention: Supplemental parenteral nutrition strategy for 7 days post randomisation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care with enteral nutrition
Number of subjects: 100
Study: 23557411

Group type: EXPERIMENTAL
Intervention: Octreotide (100 μg subcutaneously every 8 h; n = 32)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Octreotide (n = 32)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Patients with adenocarcinoma
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Patients with duct diameter >5 mm
Number of subjects: 62
Study: 20450369

Group type: EXPERIMENTAL
Intervention: AMSA injection
Number of subjects: 50
Study: 18549361

Group type: EXPERIMENTAL
Intervention: Continuous opioid therapy (COT)
Number of subjects: 0
Study: 16389581

Group type: EXPERIMENTAL
Intervention: Vocational therapy approaches
Number of subjects: 227

Group type: COMPARATOR
Intervention: Creativity-oriented ergotherapy
Number of subjects: 227
Study: 14721820

Group type: EXPERIMENTAL
Intervention: Off-pump CABG with controlled hemodilution (Group 3)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Off-pump CABG without hemodilution (Group 2)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass techniques (Group 1)
Number of subjects: 300
Study: 10698876

Group type: EXPERIMENTAL
Intervention: Six week domiciliary occupational therapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Routine follow up (Control)
Number of subjects: 138
Study: 9098588

Group type: EXPERIMENTAL
Intervention: Mibefradil added to standard therapy for heart failure
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 2400
Study: 1286418

Group type: EXPERIMENTAL
Intervention: 26 gauge needles
Number of subjects: 160

Group type: COMPARATOR
Intervention: 22 gauge needles
Number of subjects: 160
Study: 3954110

Group type: COMPARATOR
Intervention: Lidocaine plus 0.5 ml normal saline (Group 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lidocaine plus 0.3 mg epinephrine (Group 2)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lidocaine plus 5 mg phenylephrine (Group 3)
Number of subjects: 28
Study: 29962178

Group type: EXPERIMENTAL
Intervention: Exercise (EX trial) - walking for 1 hour at 50% V̇O₂max
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON trial) - resting
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Exercise (EX trial)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON trial)
Number of subjects: 9
Study: 27015267

Group type: EXPERIMENTAL
Intervention: Icotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study: 25554429

Group type: EXPERIMENTAL
Intervention: Ketamine (20 & 40mg/70kg/h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (sham condition)
Number of subjects: 12
Study: 23958263

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 6 months
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 20634355

Group type: EXPERIMENTAL
Intervention: Fentanyl (lumbar intrathecal)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (interspinous saline, L(3)-L(4))
Number of subjects: 5
Study: 18155934

Group type: EXPERIMENTAL
Intervention: Exposure plus usual treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waiting list control plus usual treatment
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: All patients treated (pre to post-treatment)
Number of subjects: 46
Study: 16177596

Group type: EXPERIMENTAL
Intervention: 30 g UWP/d
Number of subjects: 18

Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: UWP and Casein placebo
Number of subjects: 18
Study: 12933391

Group type: EXPERIMENTAL
Intervention: 5% lidocaine-prilocaine (EMLA) cream
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lidocaine added to propofol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 90
Study: 10376858

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 46
Study: 14588914

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (printed manual and therapist meeting prior to discharge)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine hospital treatment and discharge instructions (control group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 58
Study: 1991923

Group type: EXPERIMENTAL
Intervention: IgE antibody specific for formaldehyde-human serum albumin detected by ELISA in three subjects.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Respiratory challenge with formaldehyde at concentrations of up to 2 ppm.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Serum from three subjects with IgE to formaldehyde-human serum albumin by ELISA.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: IgG to formaldehyde-human serum albumin detected by ELISA in three subjects and two other subjects.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Overall study findings.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Study conclusion.
Number of subjects: 55
Study: 6109741

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 8 mg (single dose)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 8 mg (seven doses)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg (single dose)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg (seven doses)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combination of chlorpheniramine and cimetidine (seven doses)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31148196

Group type: EXPERIMENTAL
Intervention: Transfusion (T) group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 15
Study: 29209630

Group type: EXPERIMENTAL
Intervention: Active participants
Number of subjects: 192

Group type: COMPARATOR
Intervention: Inactive participants
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Level of education
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Fear of pain
Number of subjects: 192
Study: 26596670

Group type: COMPARATOR
Intervention: Chemotherapy plus lenalidomide (six cycles of cyclophosphamide [300 mg/m2, days 1, 8, and 15], dexamethasone [40 mg, days 1, 8, 15, and 22], and lenalidomide [25 mg, days 1-21])
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: High-dose melphalan (200 mg/m2) and ASCT
Number of subjects: 389

Group type: COMPARATOR
Intervention: Lenalidomide (10 mg, days 1-21) plus prednisone (50 mg, every other day)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Lenalidomide alone
Number of subjects: 389

Group type: COMPARATOR
Intervention: Chemotherapy plus lenalidomide
Number of subjects: 389
Study: 24062812

Group type: COMPARATOR
Intervention: Personalised evaluations
Number of subjects: 615

Group type: COMPARATOR
Intervention: Anonymous evaluations
Number of subjects: 615
Study: 21931035

Group type: EXPERIMENTAL
Intervention: R‐CHOP‐21
Number of subjects: 300

Group type: COMPARATOR
Intervention: R‐CHOP‐14
Number of subjects: 300
Study: 19672606

Group type: EXPERIMENTAL
Intervention: PCCP (Percutaneous Compression Plate)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gamma 3 intramedullary nail
Number of subjects: 80
Study: 15226056

Group type: EXPERIMENTAL
Intervention: 24-week aerobic and weight-training exercise plus behavior modification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 11407998

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study: 9215300

Group type: EXPERIMENTAL
Intervention: 0.1 mU.kg‐1.min‐1 euglycemic insulin clamp
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.4 mU.kg‐1.min‐1 euglycemic insulin clamp
Number of subjects: 6

Group type: COMPARATOR
Intervention: iv 0.9% NaCl infusion after oral acipimox administration (250 mg)
Number of subjects: 6
Study: 8573453

Group type: EXPERIMENTAL
Intervention: Chemopreventive agents such as retinoids and tamoxifen
Number of subjects: 0
Study: 2223687

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate, 1 mg (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate, 0.5 mg (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Megestrol acetate, 5 mg (group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Megestrol acetate, 2.5 mg (group D)
Number of subjects: 60
Study: 573602

Group type: EXPERIMENTAL
Intervention: Kallikrein (600 units porcine pancreatic kallikrein daily for 7 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (daily for 7 weeks)
Number of subjects: 90
Study: 31680410

Group type: EXPERIMENTAL
Intervention: CT emulgel (4% Cinnamomum tamala extract)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (base)
Number of subjects: 13
Study: 30793698

Group type: EXPERIMENTAL
Intervention: Permissive temperature threshold (39.5°C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Restrictive temperature threshold (37.5°C)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (Permissive and Restrictive)
Number of subjects: 100
Study: 28645255

Group type: EXPERIMENTAL
Intervention: Artemisinin combination therapy (ACT)
Number of subjects: 8897

Group type: COMPARATOR
Intervention: Non-ACT
Number of subjects: 8897
Study: 26347106

Group type: EXPERIMENTAL
Intervention: UFT/LV for 5 consecutive days per week for 18 months
Number of subjects: 1071

Group type: COMPARATOR
Intervention: UFT/LV for 6 months (28 of 35 days)
Number of subjects: 1071
Study: 24256373

Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no isotretinoin treatment)
Number of subjects: 44
Study: 21947320

Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day plus modafinil 200 mg/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Risperidone 6 mg/day plus placebo
Number of subjects: 46
Study: 20622703

Group type: EXPERIMENTAL
Intervention: Lens type III
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control spectacle lenses
Number of subjects: 210
Study: 17156104

Group type: EXPERIMENTAL
Intervention: Sitagliptin 5, 12.5, 25 or 50 mg b.i.d.
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Glipizide 5 mg/day (titrated up to 20 mg/day)
Number of subjects: 743

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Sitagliptin (all doses)
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 743
Study: 16044202

Group type: EXPERIMENTAL
Intervention: Onlay polypropylene mesh repair (group A)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Double mesh intraperitoneal repair (group B)
Number of subjects: 41
Study: 12095672

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 9120502

Group type: EXPERIMENTAL
Intervention: Serum levels of ICAM‐1 in patients with ischaemic stroke
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Serum levels of E-selectin in patients with ischaemic stroke
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Leucocyte count in patients with ischaemic stroke
Number of subjects: 51
Study: 8372418

Group type: EXPERIMENTAL
Intervention: Intraoperative application of fibrin glue
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Higher doses of immunosuppressants in adults
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High doses of immunosuppressants in children
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative lymph composition
Number of subjects: 100
Study: 3733830

Group type: EXPERIMENTAL
Intervention: 135 degrees Jewett nail-plate
Number of subjects: 98

Group type: COMPARATOR
Intervention: 135 degrees Dynamic hip screw
Number of subjects: 98
Study: 30067737

Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 184

Group type: COMPARATOR
Intervention: Face-to-face education (Control)
Number of subjects: 184
Study: 26701155

Group type: EXPERIMENTAL
Intervention: Behavioural intervention promoting an active lifestyle after discharge (13 individual sessions delivered by a coach trained in motivational interviewing; began 2 months before and ended 6 months after discharge)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Regular rehabilitation including handcycle training (control group)
Number of subjects: 45
Study: 24607295

Group type: EXPERIMENTAL
Intervention: Online asthma management program (4 online sessions)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control asthma management program (4 online sessions)
Number of subjects: 500
Study: 22176598

Group type: EXPERIMENTAL
Intervention: High meaningfulness and high integrative processing instruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meaningfulness instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expressive writing intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meaningfulness and integrative processing instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported meaningfulness of the writing
Number of subjects: 0
Study: 20068423

Group type: EXPERIMENTAL
Intervention: Maintenance training (MT) for 1 year, including weekly supervised training for the first 6 months, bi-weekly supervised training for the next 6 months, and no supervised training for the last 6 months.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (unsupervised training at home).
Number of subjects: 96
Study: 18773755

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 6600

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 6600

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 6600
Study: 16162814

Group type: EXPERIMENTAL
Intervention: Total serum homocysteine (tHcy) levels
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Baseline cardiovascular disease
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Diastolic BP
Number of subjects: 1575
Study: 12184901

Group type: EXPERIMENTAL
Intervention: MIST-VR (5 sessions, 6 skills/session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yale Skills Course (5 sessions, 3 skills/session)
Number of subjects: 0
Study: 10087737

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA)
Number of subjects: 341

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: All groups (EA, SA, GA)
Number of subjects: 341
Study: 7489965

Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alfa2b 5 MU/m2 thrice weekly for 4 months, continued up to 12 months if ALT reduced by at least 50%
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alfa2b
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 27
Study: 1683682

Group type: COMPARATOR
Intervention: H. influenzae type b polysaccharide (PRP) vaccine
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Polysaccharide‐mutant diphtheria toxoid conjugate vaccine (PRP‐CRM)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 248
Study: 6982989

Group type: EXPERIMENTAL
Intervention: CSFHU 10(6) units intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CSFHU 5 x 10(5) units intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CSFHU 1.3 to 1.4 x 10(7) units intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CSFHU 7 x 10(6) units intravenously
Number of subjects: 12
Study: 31894038

Group type: EXPERIMENTAL
Intervention: Enteral nutrition support therapy combined with antibiotics (azithromycin plus cefuroxime sodium)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Parenteral nutritional support therapy combined with antibiotics (azithromycin plus cefuroxime sodium)
Number of subjects: 90
Study: 30357266

Group type: EXPERIMENTAL
Intervention: Prophylactic hypothermia (33°C-35°C for at least 72 hours, up to 7 days if intracranial pressures were elevated)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Normothermic management (targeting 37°C)
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Prophylactic hypothermia
Number of subjects: 511

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 511
Study: 27052036

Group type: EXPERIMENTAL
Intervention: Melatonin cream 12.5% applied on 80% of body surface area
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned in the abstract)
Number of subjects: 10
Study: 24694876

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 60
Study: 22250853

Group type: EXPERIMENTAL
Intervention: Positive response to MDD treatment
Number of subjects: 192

Group type: COMPARATOR
Intervention: Initial MDD treatment (CBT, FLX, COMB, PBO)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Prior involvement with alcohol or drugs
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: More comorbid disorders
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Recurrent MDD and AUD
Number of subjects: 192
Study: 19489492

Group type: EXPERIMENTAL
Intervention: Chuzhen therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acupuncture therapy
Number of subjects: 60
Study: 17360077

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS)
Number of subjects: 19
Study: 15006466

Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 100 mg modafinil
Number of subjects: 45
Study: 11769996

Group type: EXPERIMENTAL
Intervention: Prednisone tablets
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Carbogen inhalation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Room air inhalation
Number of subjects: 41
Study: 10065224

Group type: EXPERIMENTAL
Intervention: Child RAND (asthma group)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Child RAND (control group)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Child RAND (children with health complaints)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Child RAND (children without health complaints)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Sensitivity to change of Child RAND
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Reliability and validity measures of Child RAND
Number of subjects: 348
Study: 8021796

Group type: EXPERIMENTAL
Intervention: Single unit of packed red blood cells until expiration (35 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2503490

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg, orally)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 790293

Group type: EXPERIMENTAL
Intervention: methylphenidate
Number of subjects: 47

Group type: COMPARATOR
Intervention: imipramine
Number of subjects: 47
Study: 31279405

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 2764

Group type: COMPARATOR
Intervention: Biolimus-eluting stents (BES)
Number of subjects: 2764
Study: 28120497

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg (with optional uptitration to 300 mg)
Number of subjects: 5812

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5812
Study: 29911577

Group type: EXPERIMENTAL
Intervention: Experimental knee pain (hypertonic saline injection)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (isotonic saline injection)
Number of subjects: 10
Study: 23144045

Group type: EXPERIMENTAL
Intervention: Forced cycling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Voluntary cycling
Number of subjects: 0
Study: 21227540

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous metoclopramide
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: 20 mg intravenous metoclopramide
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: 40 mg intravenous metoclopramide
Number of subjects: 356

Group type: COMPARATOR
Intervention: Overall study population
Number of subjects: 356
Study: 18306984

Group type: EXPERIMENTAL
Intervention: Second-line treatment with pantoprazole (40 mg twice daily), amoxicillin (1000 mg twice daily), and clarithromycin (500 mg) for 7 days
Number of subjects: 134

Group type: COMPARATOR
Intervention: Second-line treatment with ranitidine bismuth citrate (400 mg twice daily), metronidazole (250 mg twice daily), and clarithromycin (500 mg) for 7 days
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Third-line quadruple therapies with pantoprazole + amoxicillin and tetracycline (500 mg four times daily) and either nitrofurantoin (100 mg three times daily) or bismuth subsalicylate (120 mg four times daily)
Number of subjects: 134
Study: 17175821

Group type: EXPERIMENTAL
Intervention: Chloral hydrate, meperidine, and hydroxyzine (regimen A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Midazolam, meperidine, and hydroxyzine (regimen B)
Number of subjects: 16
Study: 12676059

Group type: EXPERIMENTAL
Intervention: First-order (luminance-defined) motion stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-order (texture-defined) motion stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0